September, 2016:

• Lenalidomide Maintenance Recommended in Myeloma Post-transplant
• ASTRO: Study Affirms Efficacy of Doxepin Rise for Treatment of Oral Mucositis Pain
• Adding CVP ± Rituximab After IFRT Improves PFS vs IFRT Alone in Stage 1-2 Follicular Lymphoma
• Calcifications Linked With Favorable, Unfavorable Prognostic Factors in Breast Cancer
• Height and Melanoma Risk: What's the Takeaway?
• Metastasis More Than Doubles With Monitoring Instead of Treatment for Localized Prostate Cancer
• Use of SBRT Improves OS Rates Among Veterans With Stage I NSCLC
• Tumor-specific Biomarkers Predict Response in HER-2-positive Breast Cancer
• Survival Rate Rising Among Elderly Patients With NSCLC Treated With SBRT
• The Next Frontier: Radiotherapy Plus Immunotherapy for Melanoma Brain Metastases
• Carfilzomib + Melphalan, Prednisone Fails to Improve PFS in Myeloma
• Encorafenib + Binimetinib Improves PFS Versus Vemurafenib Alone in Melanoma
• Combination Therapy May Improve Survival in Nasopharyngeal Carcinoma
• No Difference in PFS Between RT and Temozolomide in Glioma
• Q&A With Samanta Kumar Pal, MD: Prostate Cancer Androgen Deprivation and "Drug Holidays"
• Defibrotide for Hepatic Sinusoidal Obstruction Syndrome in Hematopoietic Stem Cell Transplant
• PSA Testing Unchanged in Years After USPSTF Recommendation
• MRI May Be Effective Screening Test for Hepatocellular Carcinoma
• Risk of Arrhythmias, Bleeding Higher With Ibrutinib Therapy
• Prolonged Imatinib Therapy Linked With Deeper Molecular Response in CML-CP
• Emerging Prognostic Markers Continue to Improve Myeloma Treatment
• Study Emphasizes Importance of Skin Exams for Organ Transplant Recipients
• Alpha-fetoprotein Levels May Predict HCC Response to Ramucirumab
• TP53, MDM2 Alterations Linked to Cisplatin Resistance in Testicular Cancer
• Post-mastectomy Radiotherapy Reduces Risk for Locoregional Failure, Recurrence
• Circulating Plasma Cells Predict Poor Prognosis in Multiple Myeloma
• Combined Treatment May Lead to Cure for Chronic Myeloid Leukemia
• Response Rate Similar Between Low- and Standard-dose Ponatinib
• Ibrutinib Linked With Favorable Survival, High Response Rate in CLL
• Imatinib Less Beneficial for Patients With CML in Accelerated Phase
• Q&A With Dr Sarah Vinnicombe: Use Breast MRI Judiciously for Optimal Outcomes
• Ghost and Honorary Authorship in Cancer Research
• Coping With Waldenstrom Macro-globulinemia
• FDA Accepts NDA for Neratinib in HER2+ Early Stage Breast Cancer
• Bevacizumab Not Recommended in Adjuvant Colorectal Cancer Treatment
• Dalantercept Monotherapy Study Misses Endpoint
• Addition of Rituximab to Chemo Provides Survival Benefit in Acute Leukemia
• Immunotherapy-related Pneumonitis More Common With Combo Therapy
• Statins Linked to Improved Overall Survival in Multiple Myeloma
• Treating TKI-induced Hypertension in Renal Cell Carcinoma
• Immune Checkpoint Inhibitors Continue to Transform Management of Advanced NSCLC
• G-CSF Linked With Some Reduction in Neutropenia-related Hospitalization
• Population Disparity in NCI Studies Still Needs Improvement
• CTA Treatment Regimen Chart for Esophageal and EGJ Cancers Updated
• Fixed-dose Pembrolizumab Induces Durable Responses in HNSCC
• Oral REP Regimen Active in Myeloma Refractory to Lenalidomide
• Vasectomy Unlikely to Be a Causal Factor of Aggressive Prostate Cancer
• Minimal Residual Disease and Treatment Response in Multiple Myeloma
• Decline in Use of Digital Rectal Examination, PSA Testing
• Recent Decline in Cancer Mortality Among Teenagers, Children
• Testosterone Appears Safe for Hypogonadal Patients With Prostate Cancer
• 2016 Concordia Summit: The Future of Immunotherapy
• Ricolinostat Appears Safe in Relapsed/Refractory Myeloma
• Massage Therapy May Reduce Chemo-induced Peripheral Neuropathy
• FDA Modifies Nivolumab Dosage Regimens for RCC, NSCLC, Melanoma
• MRD-negative Status Linked With Better Survival in Multiple Myeloma
• Lenalidomide Active in R/R Adult T-cell Leukemia/Lymphoma
• Overspending on Antiemetic Drugs Not Decreasing, Despite ASCO Guidelines
• Q&A With Dana Carroll, PhD, Highlights CRISPR's Growing Role in Genome Editing
• Metabolic Tumor Volume Predicts Outcome in Follicular Lymphoma
• Everolimus Associated With Longest mOS Observed Among Patients With Advanced pNET
• Prostate Cancer Mortality May Be Consistent Regardless of Treatment Choice
• Assessing Mindfulness-based Cognitive Therapy For Cancer Pain
• Urinary, Sexual Function Vary by Treatment Type in Localized Prostate Cancer
• Ibrutinib Active in Patients With R/R CLL and 17p Deletion
• Dexamethasone-based Mouthwash for Stomatitis Prevention
• Uridine Triacetate May Be Safe, Effective Treatment for Capecitabine/5-FU Overdose
• Cabazitaxel Active in Docetaxel-resistant Non-small Cell Lung Cancer
• The Evolutionary Implications of CRISPR-Cas9 for Clinical Oncology
• Enforcing Reproducibility Improves the Accuracy of Scientific Predictions
• Second-line mFOLFOX6 and FU/LV for Pancreatic Cancer
• Adding Palifosfamide to Doxorubicin Fails to Improve PFS in Sarcoma
• Strategies for Treatment of Patients With Ductal Carcinoma in Situ Evaluated
• Use of Higher SPF Sunscreen Linked With Lower Melanoma Risk
• Olaparib Maintenance Fails to Significantly Prolong Survival in Ovarian Cancer
• Effective Patient-Oncologist Communication Training Recommended
• Phase 2 CheckMate 069 Study Suggests Nivolumab Plus Ipilimumab May Improve Overall Survival in Melanoma
• Chronic Sinusitis Linked With Head and Neck Cancers
• Endoscopic Ultrasound and Pancreatic Cancer Screening
• FDA Grants Priority Review to Pembrolizumab for Frontline Treatment of NSCLC
• Afatinib Dose Adjustment Improves Tolerability Without Affecting Efficacy in NSCLC
• Cord-blood Transplant Donations Improve Survival of Patients With Acute Leukemia or Myelodysplastic Syndrome
• Combination Immunotherapy Promising for Treatment of Renal Cell Carcinoma
• TKI-intolerant Patients With CLL Can Successfully Receive an Alternate TKI
• KRd Improves QoL vs Rd Alone in Multiple Myeloma
• Overdetection Explains Increased Prevalence of Thyroid Cancer
• Checkpoint Inhibitors and Combination Therapy: the Future of Treatment for Non-small Cell Lung Cancer?
• Breast Cancer Risk and Psychosocial Adjustment Among Adolescents
• Integrating Palliative Care Early Improves QOL of Patients With Incurable Cancer
• "Mystery Shopper" Study Identifies Barriers to Palliative Care Access
• VEGF/mTOR-directed Combination Shows Promise in Renal Cell Carcinoma
• Biological Implications of Obesity Linked to Survival of Patients With Renal Cell Carcinoma
• CTA Treatment Regimen Chart for Melanoma Updated
• Selinexor Effects Responses in Refractory Myeloma
• Avelumab Induces Durable Responses in Merkel Cell Carcinoma
• Whole Brain Radiotherapy Offers Little Benefit to Patients With Brain-metastatic Lung Cancer
• Mortality From Ovarian Cancer on Decline in the West
• Melanoma Treatment Regimens
• Atezolizumab Significantly Improves OS in Locally Advanced or Metastatic NSCLC
• FDA Approves Blinatumomab for Pediatric B-cell Precursor ALL
• ADI-PEG20 Improves PFS in ASS1-deficient Mesothelioma
• Vandetanib Fails to Benefit Patients With Small Cell Lung Cancer
• Managing PD-1 Inhibitor-induced Pneumonitis
• Ongoing ADT Use Up to 36 Months Not Linked With Cognitive Decline
• Mortality Risk Higher With Genetic Duet in Papillary Thyroid Cancer
• Dronabinol Oral Solution Approved for CINV
• Enoxaparin Reduces Occurrence of Venous Thromboembolic Events
• Age May be Prognostic Factor in Ovarian Cancer
• Breast Density and Risk Factors Indicate Breast Cancer Screening Intervals
• Bone Marrow Transplantation as a Treatment Option: What You Need to Know